SCHEMBL7527263

SCHEMBL7527263

CCOC(=O)C(=O)N1CCCC1CCC(C)=O

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
GAA P10253 1/20 0.40
GABRA1 P14867 3/20 0.37
GABRG2 P18507 3/20 0.37
GABRB3 P28472 3/20 0.37
GABRA3 P34903 3/20 0.37
GABRA2 P47869 3/20 0.37
GABRB2 P47870 3/20 0.37
FKBP1A P62942 4/20 0.36
ALDH1A1 P00352 1/20 0.33
NPC1 O15118 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7527256 1.00 L3MBTL1 (0.42) L3MBTL1POLBMAPTGAAGABRA1
SCHEMBL7527522 0.89 L3MBTL1 (0.44) L3MBTL1POLBMAPTGAAGABRA1
SCHEMBL7527526 0.89 L3MBTL1 (0.44) L3MBTL1POLBMAPTGAAGABRA1
SCHEMBL10034628 0.76 FKBP1A (0.48) L3MBTL1MAPTGAAFKBP1AALDH1A1
SCHEMBL14829164 0.75 GABRA1 (0.50) L3MBTL1POLBMAPTGAAGABRA1
SCHEMBL2041988 0.74 ALDH1A1 (0.40) L3MBTL1POLBGABRA1GABRG2GABRB3
SCHEMBL19947209 0.74 ALDH1A1 (0.40) L3MBTL1POLBGABRA1GABRG2GABRB3
SCHEMBL21296651 0.73 RAB9A (0.54) L3MBTL1MAPTFKBP1AALDH1A1RAB9A
SCHEMBL7639913 0.73 RAB9A (0.54) L3MBTL1MAPTFKBP1AALDH1A1RAB9A
SCHEMBL10066850 0.73 FKBP1A (0.62) MAPTGAAFKBP1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0934305-A4 INTEGRIN ANTAGONISTS MERCK & CO INC (US) 2001-04-11 EP disclosed
US-6211184-B1 TETRAHYDRO-PYRAZINE OR PYRIMIDINE DERIVATIVES; VITRONECTIN RECEPTOR ANTAGONIST; OSTEOPOROSIS; ANTIINFLAMMATORY, ANTITUMOR AGENTS; ANGIOGENESIS AND RESTENOSIS INHIBITORS MERCK & CO., INC. 2001-04-03 US disclosed
EP-0973396-A4 A METHOD OF TREATING CANCER MERCK & CO INC (US) 2001-02-07 EP disclosed
EP-0973396-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 2000-01-26 EP disclosed
US-5981546-A Integrin antagonists MERCK & CO., INC. (US) 1999-11-09 US disclosed
EP-0934305-A1 INTEGRIN ANTAGONISTS Merck & Co., Inc. (US) 1999-08-11 EP disclosed
WO-1998046220-A1 COMBINATION THERAPY FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS MERCK & CO., INC. (US) 1998-10-22 WO disclosed
WO-1998044797-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1998-10-15 WO disclosed
WO-1998008840-A1 INTEGRIN ANTAGONISTS MERCK & CO., INC. (US) 1998-03-05 WO disclosed